BioSpace News Archive

BeyondSpring Inc. announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

Pliant Therapeutics, Inc., a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced participation in the following March investor conferences.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.

Orchestra BioMed Holdings, Inc. announced the presentation of new data demonstrating the long-term effect of atrioventricular interval modulation therapy on generating clinically-meaningful reductions in 24-hour ambulatory systolic blood pressure in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.

Standard BioTools Inc. and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing.

Aucta Pharmaceuticals, Inc. announced the commercial launch of MOTPOLY XR extended-release capsules C-V. MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

XYRA LLC is pleased to announce today it has reached agreement with the FDA (“Agency”) at a series of End of Phase 2 (EoP2) meetings, on the key studies that will form the basis of approval and labeling of orally administered budiodarone for the long-term management of symptomatic non-permanent atrial fibrillation (AF).

Lirum Therapeutics, Inc. (“Lirum”) announced today that it will present positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R), in patients with high IGF-1R tumor expression at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.

Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.